The ongoing battle for mifepristone access and abortion pill restrictions.

The pharmaceutical industry has warned that if court orders to limit or undo the FDA's approval of mifepristone, a commonly used abortion medication, are allowed to stand, it could have far-reaching effects beyond abortion. The industry has escalated its warnings, with more than 500 pharmaceutical executives and researchers signing an open letter declaring that a decision to side with the conservative groups in curtailing access to mifepristone would result in "uncertainty for the entire biopharma industry." The lawsuit, filed by a coalition of anti-abortion groups and doctors, takes aim at nearly every step of the FDA's regulatory process.